Cargando…
End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498491/ http://dx.doi.org/10.1016/j.jns.2021.118177 |
| _version_ | 1784580171413585920 |
|---|---|
| author | Magro, Giuseppe De Martino, Antonio Tosto, Federico Santangelo, Domenico Manzo, Lucia Bruno, Pietro Pascarella, Angelo Pasquale, Marilisa Barone, Stefania Gambardella, Antonio Valentino, Paola |
| author_facet | Magro, Giuseppe De Martino, Antonio Tosto, Federico Santangelo, Domenico Manzo, Lucia Bruno, Pietro Pascarella, Angelo Pasquale, Marilisa Barone, Stefania Gambardella, Antonio Valentino, Paola |
| author_sort | Magro, Giuseppe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8498491 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84984912021-10-08 End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab Magro, Giuseppe De Martino, Antonio Tosto, Federico Santangelo, Domenico Manzo, Lucia Bruno, Pietro Pascarella, Angelo Pasquale, Marilisa Barone, Stefania Gambardella, Antonio Valentino, Paola J Neurol Sci Article Elsevier 2021-10 2021-10-08 /pmc/articles/PMC8498491/ http://dx.doi.org/10.1016/j.jns.2021.118177 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Magro, Giuseppe De Martino, Antonio Tosto, Federico Santangelo, Domenico Manzo, Lucia Bruno, Pietro Pascarella, Angelo Pasquale, Marilisa Barone, Stefania Gambardella, Antonio Valentino, Paola End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab |
| title | End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab |
| title_full | End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab |
| title_fullStr | End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab |
| title_full_unstemmed | End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab |
| title_short | End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab |
| title_sort | end of dose interval (edi) symptoms in patients undergoing treatment with natalizumab |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498491/ http://dx.doi.org/10.1016/j.jns.2021.118177 |
| work_keys_str_mv | AT magrogiuseppe endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT demartinoantonio endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT tostofederico endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT santangelodomenico endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT manzolucia endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT brunopietro endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT pascarellaangelo endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT pasqualemarilisa endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT baronestefania endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT gambardellaantonio endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab AT valentinopaola endofdoseintervaledisymptomsinpatientsundergoingtreatmentwithnatalizumab |